Immunotherapy drugs targeting PD-1/PD-L1 have demonstrated notable benefits in treating pediatric classic Hodgkin lymphoma, with the disease’s biology playing a crucial role in determining treatment response. This evidence concerns the gene CD274 and Hodgkins lymphoma.